FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026514919> ?p ?o ?g. }

• W2026514919 endingPage "65" @default.
• W2026514919 startingPage "59" @default.
• W2026514919 abstract "Anti-angiogenic agents, such as bevacizumab (BEV), can induce normalization of the blood brain barrier, which may influence the penetration and activity of a co-administered cytotoxic drug. However, it is unknown whether this effect is associated with a benefit in overall survival. This study employed intracranial human glioma models to evaluate the effect of BEV alone and in combination with temozolomide (TMZ) and/or radiation therapy (XRT) on overall survival. One hundred eight male athymic rats were intracranially injected with either U251 or U87 human glioma. Ten or eleven days after tumor inoculation, animals bearing U251 and U87, respectively, were treated with: TMZ alone (50 mg/kg for 5 consecutive days, P.O.), BEV alone (15 mg/kg, I.V.), a combination of TMZ and BEV, or a combination of TMZ, BEV, and a single fraction of XRT (20 Gy). Controls received no treatment. The U87 experiment was repeated and the relationship between survival and the extent of anti-angiogenesis via anti-laminin antibodies for the detection of blood vessels was assessed. In both U87 glioma experiments, all of the treatment groups had a statistically significant increase in survival as compared to the control groups. Also, for both U87 experiments the combination groups of TMZ and BEV had significantly better survival when compared to either treatment administered alone, with 75 % of animals demonstrating long-term survival (LTS) (defined as animals alive 120 days after tumor implantation) in one experiment and 25 % LTS in the repeat experiment. In the U251 glioma experiment, all treated groups (except BEV alone) had significantly improved survival as compared to controls with minimal statistical variance among groups. The percent vessel area was lowest in the group of animals treated with BEV alone. The addition of BEV to TMZ and/or XRT had variable effect on prolonging survival in the two human glioma models tested with reduced tumor vascularity in groups treated with BEV. These results indicate that BEV has anti-angiogenic activity and does not seem to hinder the effect of TMZ." @default.
• W2026514919 created "2016-06-24" @default.
• W2026514919 creator A5010219978 @default.
• W2026514919 creator A5021438323 @default.
• W2026514919 creator A5022565141 @default.
• W2026514919 creator A5027043430 @default.
• W2026514919 creator A5037279124 @default.
• W2026514919 creator A5049334243 @default.
• W2026514919 creator A5051287778 @default.
• W2026514919 creator A5072288108 @default.
• W2026514919 creator A5077535712 @default.
• W2026514919 creator A5079378247 @default.
• W2026514919 creator A5084077497 @default.
• W2026514919 date "2013-11-02" @default.
• W2026514919 modified "2023-10-18" @default.
• W2026514919 title "Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models" @default.
• W2026514919 cites W1965642226 @default.
• W2026514919 cites W1996810856 @default.
• W2026514919 cites W2010993787 @default.
• W2026514919 cites W2013749488 @default.
• W2026514919 cites W2015344488 @default.
• W2026514919 cites W2055009621 @default.
• W2026514919 cites W2070412580 @default.
• W2026514919 cites W2092409918 @default.
• W2026514919 cites W2096287682 @default.
• W2026514919 cites W2106823541 @default.
• W2026514919 cites W2126890008 @default.
• W2026514919 cites W2131480590 @default.
• W2026514919 cites W2132697290 @default.
• W2026514919 cites W2147535764 @default.
• W2026514919 cites W2158681922 @default.
• W2026514919 cites W2163458899 @default.
• W2026514919 cites W2170367762 @default.
• W2026514919 doi "https://doi.org/10.1007/s11060-013-1268-2" @default.
• W2026514919 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4037922" @default.
• W2026514919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24185441" @default.
• W2026514919 hasPublicationYear "2013" @default.
• W2026514919 type Work @default.
• W2026514919 sameAs 2026514919 @default.
• W2026514919 citedByCount "24" @default.
• W2026514919 countsByYear W20265149192014 @default.
• W2026514919 countsByYear W20265149192015 @default.
• W2026514919 countsByYear W20265149192016 @default.
• W2026514919 countsByYear W20265149192017 @default.
• W2026514919 countsByYear W20265149192018 @default.
• W2026514919 countsByYear W20265149192019 @default.
• W2026514919 countsByYear W20265149192020 @default.
• W2026514919 countsByYear W20265149192021 @default.
• W2026514919 countsByYear W20265149192022 @default.
• W2026514919 crossrefType "journal-article" @default.
• W2026514919 hasAuthorship W2026514919A5010219978 @default.
• W2026514919 hasAuthorship W2026514919A5021438323 @default.
• W2026514919 hasAuthorship W2026514919A5022565141 @default.
• W2026514919 hasAuthorship W2026514919A5027043430 @default.
• W2026514919 hasAuthorship W2026514919A5037279124 @default.
• W2026514919 hasAuthorship W2026514919A5049334243 @default.
• W2026514919 hasAuthorship W2026514919A5051287778 @default.
• W2026514919 hasAuthorship W2026514919A5072288108 @default.
• W2026514919 hasAuthorship W2026514919A5077535712 @default.
• W2026514919 hasAuthorship W2026514919A5079378247 @default.
• W2026514919 hasAuthorship W2026514919A5084077497 @default.
• W2026514919 hasBestOaLocation W20265149192 @default.
• W2026514919 hasConcept C126322002 @default.
• W2026514919 hasConcept C128473837 @default.
• W2026514919 hasConcept C143998085 @default.
• W2026514919 hasConcept C203014093 @default.
• W2026514919 hasConcept C2776694085 @default.
• W2026514919 hasConcept C2777389519 @default.
• W2026514919 hasConcept C2777802072 @default.
• W2026514919 hasConcept C2778227246 @default.
• W2026514919 hasConcept C2780394083 @default.
• W2026514919 hasConcept C502942594 @default.
• W2026514919 hasConcept C509974204 @default.
• W2026514919 hasConcept C71924100 @default.
• W2026514919 hasConcept C98274493 @default.
• W2026514919 hasConceptScore W2026514919C126322002 @default.
• W2026514919 hasConceptScore W2026514919C128473837 @default.
• W2026514919 hasConceptScore W2026514919C143998085 @default.
• W2026514919 hasConceptScore W2026514919C203014093 @default.
• W2026514919 hasConceptScore W2026514919C2776694085 @default.
• W2026514919 hasConceptScore W2026514919C2777389519 @default.
• W2026514919 hasConceptScore W2026514919C2777802072 @default.
• W2026514919 hasConceptScore W2026514919C2778227246 @default.
• W2026514919 hasConceptScore W2026514919C2780394083 @default.
• W2026514919 hasConceptScore W2026514919C502942594 @default.
• W2026514919 hasConceptScore W2026514919C509974204 @default.
• W2026514919 hasConceptScore W2026514919C71924100 @default.
• W2026514919 hasConceptScore W2026514919C98274493 @default.
• W2026514919 hasIssue "1" @default.
• W2026514919 hasLocation W20265149191 @default.
• W2026514919 hasLocation W20265149192 @default.
• W2026514919 hasLocation W20265149193 @default.
• W2026514919 hasLocation W20265149194 @default.
• W2026514919 hasOpenAccess W2026514919 @default.
• W2026514919 hasPrimaryLocation W20265149191 @default.
• W2026514919 hasRelatedWork W2117908127 @default.
• W2026514919 hasRelatedWork W2169869816 @default.
• W2026514919 hasRelatedWork W2353888425 @default.

• next